Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Dizal (Jiangsu) Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    688192   CNE1000055W8

DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

(688192)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-22
31.44 CNY   +0.51%
09/05Dizal Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
CI
09/05Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO
CI
08/25Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dizal Demonstrates Clinical Update for Sunvozertinib in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

08/05/2022 | 12:17am EDT

Dizal presented positive clinical updates highlighting the therapeutic potential of sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor exon 20 insertion (EGFR Exon20ins) mutation at 2022 World Conference on Lung Cancer (WCLC).
Sunvozertinib, which was granted Breakthrough Therapy Designation by US FDA and China NMPA, is a rationally designed, oral, potent EGFR Exon20ins inhibitor, with wild-type EGFR selectivity. It is currently being evaluated in late-stage development of multiple global pivotal studies as = 2nd line treatment after platinum-based chemotherapy and 1st line treatment for treatment-naïve patients. Updated findings from the studies were presented at 2022 WCLC. As of April 30, 2022, in platinum-pretreated patients (n=119), the best ORR (at the RP2D of 300mg QD) assessment according to RECIST guidelines (version 1.1) was 52.4%. In patients with baseline brain metastasis, the best ORR at 300 mg QD reached 44%. The safety profile of sunvozertinib was amenable to long-term treatment. The most common drug related TEAE (treatment emergent adverse event) were diarrhea and rash, the majority of which were Grade 1/2 and clinically manageable.


© S&P Capital IQ 2022
All news about DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
09/05Dizal Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its Fi..
CI
09/05Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Br..
CI
08/25Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30..
CI
08/05Dizal Demonstrates Clinical Update for Sunvozertinib in Platinum-Pretreated NSCLC Patie..
CI
05/05Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib Publi..
CI
04/27Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended Mar..
CI
02/25Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended Decembe..
CI
02/18Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treat..
CI
More news
Financials
Sales 2022 9,00 M 1,26 M 1,26 M
Net income 2022 -846 M -119 M -119 M
Net Debt 2022 - - -
P/E ratio 2022 -15,0x
Yield 2022 -
Capitalization 12 708 M 1 783 M 1 783 M
Capi. / Sales 2022 1 412x
Capi. / Sales 2023 146x
Nbr of Employees 234
Free-Float 45,0%
Chart DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Duration : Period :
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 31,44
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Xiao Lin Zhang Chairman & Chief Executive Officer
Hong Bin Lü CFO, Board Secretary & Director
Wei Wen Dong Chairman-Supervisory Board
Zhen Fan Yang Chief Medical Officer & Deputy General Manager
Qing Bei Zeng Chief Scientist & Deputy General Manager
Sector and Competitors
1st jan.Capi. (M$)
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.-15.05%1 783
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154